BeiGene, Ltd : BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma GlobeNewswire December 12, 2022 Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete.
New data from clinical trials of TT11 and TT11X to be featured in two oral podium presentations and a poster presentationSINGAPORE, Nov. 03, 2022 (Tessa), a clinical-stage cell therapy company developing
Multiple presentations will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl) in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma ADC Therapeutics SA (NYSE: ADCT)